Technology-enabled Management Versus Usual Care for Blood Pressure
NCT ID: NCT05479461
Last Updated: 2025-08-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
200 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-06-13
Study Completion Date
2025-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Two arm parallel randomized clinical trial
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mobile Technology for Blood Pressure Management
NCT04841317
Hypertension
COMPLETED
NA
Implementation Strategies for Self-Measured Blood Pressure Monitoring in Racially and Ethnically Diverse Populations
NCT06871462
Blood Pressure Monitoring, Home
Hypertension
RECRUITING
NA
Remote Patient Monitoring and Health Coaching vs. Usual Care for the Treatment of Hypertension
NCT05394766
Hypertension
RECRUITING
NA
Remote Monitoring and Social Support for Hypertension Management
NCT03416283
Hypertension
COMPLETED
NA
Comparing Hypertension Remote Monitoring Evaluation Redesign
NCT06113458
Hypertension
ENROLLING_BY_INVITATION
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For this study, we have 3 cohorts that employ varying recruitment strategies before they are enrolled in the interventions.
At Stanford, we have 2 cohorts, where Cohort 1 is recruiting participants through clinic screening and contacting them through text or email.
For Cohort 2, recruitment is divided into two phases: Control Phase I and Intervention Phase II. During Control Phase I, standard recruitment methods were employed, including general outreach through participating clinics and pre-existing clinical networks. These efforts did not incorporate specific strategies aimed at enhancing diversity or prioritizing underrepresented populations. In contrast, Intervention Phase II introduced four targeted strategies designed to improve the inclusion of African-American, Hispanic/Latinx individuals, and women.
1. Digital Outreach via BuildClinical: The study leverages a digital recruitment campaign managed by BuildClinical, utilizing targeted online advertisements across various platforms. Prospective participants who engage with the advertisements are directed to a study landing page, where they receive detailed study information and complete a preliminary eligibility screening before being contacted by the study team.
2. Patient Registry-Based Recruitment: Eligible participants will be identified through structured data queries from the STAnford Research Repository (STARR) or EPIC registry. This approach ensures targeted outreach to individuals who meet the study's inclusion criteria while reducing screening burden.
3. Honest Broker Outreach via Stanford RPEP: To maintain privacy compliance, the Stanford Research Participant Engagement Program (RPEP) will conduct Honest Broker outreach via multiple channels, including secure Epic MyHealth messages, postal mail, and provider co-invitations. This method allows potential participants to opt in or out before direct contact with the research team, ensuring ethical and efficient recruitment.
4. Spanish-Speaking Ambassador Program: A dedicated Spanish-speaking ambassador will support recruitment efforts by engaging with Spanish-speaking participants, providing culturally tailored study information, and assisting with the informed consent process. This initiative ensures equitable access for Spanish-speaking individuals and facilitates participation among historically underrepresented populations.
Our TIDE site partners at the Morehouse School of Medicine utilize their own recruitment methods for cohort 3, which uses the following:
Medical residents will be randomized into three screening groups using a block randomization approach to ensure demographic balance across the groups (e.g., age, years in training, prior experience). Each group will utilize a different screening method for patient recruitment:
Arm 1: Resident-Led Manual Screening
Residents apply eligibility criteria manually by reviewing patient EMRs and making judgment-based decisions.
Arm 2: AI-Assisted Screening
AI software, Deep 6, will scan EMRs for inclusion criteria and flag potentially eligible patients. Residents will then validate flagged cases to confirm or deny eligibility.
Arm 3: Coordinator-Led Screening (Control)
Coordinators screen patients independently of AI, applying eligibility criteria consistently across all patient records.
These comprehensive recruitment strategies are designed to enhance enrollment diversity, improve participant engagement, and ensure a balanced distribution of participants across study arms.
Primary and Secondary Endpoints for Cohort 1
Primary Endpoint
* Percentage of participants who consent to participate following text message compared to the percentage of participants who consent to participate following emailoutreach.
Secondary Endpoints
● Percentage of participants who consent following either text message or telephone outreach.
● Percentage of participants who consent after opting out after receiving a call or text message.
* Median time from call/text initiation to participant response among all participants who are contacted and respond.
* Percentage of African American, Hispanic, or Asian participants who consent to participate following text message compared to the percentage of African American, Hispanic, and Asian participants who consent to participate following email outreach.
* Percentage of African American or Hispanic participants who consent to participate following text message compared to the percentage of African American or Hispanic, participants who consent to participate following email outreach.
* Percentage of Asian participants who consent to participate following text message compared to the percentage of Asian participants who consent to participate following email outreach.
Primary and Secondary Endpoints for Cohort 2
Primary Endpoint
● Percentage of participants enrolled who are either African-American or Hispanic/LatinX during Intervention Phase II compared to Control Phase I.
Secondary Endpoints
● Percentage of African-American or Hispanic/LatinX participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of Hispanic/LatinX participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of African-American participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of women participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of African-American, Hispanic/LatinX, or women participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of African-American, Hispanic/LatinX, or women participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of Hispanic/LatinX participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of African-American participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of women participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of African-American or Hispanic/LatinX participants contacted through Honest Broker and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants in Control Phase I.
● Percentage of women participants contacted through Honest Broker and enrolled during Intervention Phase II compared to the percentage of women participants in Control Phase I.
● Percentage of African-American or Hispanic/LatinX participants contacted through Patient Registry and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants in Control Phase I.
● Percentage of women participants contacted through Patient Registry and enrolled during Intervention Phase II compared to the percentage of women in Control Phase I.
* Percentage of African-American or Hispanic/LatinX participants contacted through BuildClinical and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants contacted in Control Phase I.
* Percentage of women participants contacted through BuildClinical and enrolled during Intervention Phase II compared to Percentage of women participants enrolled in Control Phase I.
* Percentage of Hispanic/LatinX participants contacted through Lay Coordinator and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants contacted in Control Phase I.
Primary and Secondary Endpoints for Cohort 3
Primary Endpoint ● Screening Accuracy: Accuracy metrics include true positive, true negative, false positive, and false negative rates across the three arms, providing insight into each method's reliability and potential for error.
Secondary Endpoints ● Representativeness: This measures the number and characteristics (e.g., age, race/ethnicity) of patients recruited in each arm, allowing for assessment of demographic representativeness.
● Enrollment Screening Efficiency: This is measured as the average time per screened patient across the three arms. Efficiency will be assessed based on total time to screen each patient from record access to eligibility determination.
* Workload and Satisfaction: Surveys will capture resident and coordinator perceptions of workload, satisfaction, and feasibility of each method, with Likert scales and qualitative feedback (Ellis \& Kasperbauer, 2020).
Statistical Analysis Plan (SAP) Cohort 1 Analysis Methods
The proportion of participants who consent following text message or email-telephoneoutreach will be calculated. Median and interquartile range will be estimated for the time from email /text initiation to participant response.
Cohort 2 Analysis Methods This study aims to increase recruitment through a two-phase trial that will compare a combination of recruitment strategies through 3 distinct cohort-based recruitment strategies to assess their effectiveness to improve participant diversity and engagement. Participants are control phase I or intervention phase II.
The primary statistical test will be a two-sample Z-test for proportions, comparing enrollment percentages in African American/Black and Hispanic/Latino between the control phase I and intervention phase II. The same method will be applied to the secondary endpoints, comparing recruitment rates across demographic subgroups and different recruitment strategies. All tests will be one-sided with α=0.05.
Based on the preliminary data from February 2025, the control phase enrolled 135 participants, with the following distributions:
* African American/Black: 8 (5.92%)
* Hispanic/Latino: 17 (12.6%)
The intervention phase II aims for a 50% increase in African American/Black and Hispanic/Latino enrollment. With a total of 270 participants (135 per phase), the power calculation indicates that the statistical power to detect this significant increase is 100%.
Cohort 3 Analysis Methods This cohort will evaluate the efficiency, accuracy, satisfaction, and representativeness across the three screening arms. The primary metric for assessing efficiency will be the mean screening time per patient. A one-way ANOVA will be conducted to compare mean screening times among the arms, followed by post-hoc tests if significant overall differences are detected. For accuracy, the analysis will be based on true and false positive/negative rates across screening methods. Chi-square tests will be used for categorical comparisons, and logistic regression will be applied to control for potential confounding variables, such as resident training level and experience. Representativeness and satisfaction will be evaluated through the analysis of demographic characteristics, including age, race, and gender along with responses to surveys assessing workload and satisfaction. Chi-square tests will be used to analyze categorical demographic data, while the Kurskal-Wallis test will be employed to compare non-parametric Likert-scale responses across all study arms. Additionally, open-ended feedback will be thematically analyzed to enrich the interpretation of quantitative findings.
At Stanford, we have 2 cohorts, where Cohort 1 is recruiting participants through clinic screening and contacting them through text or email.
For Cohort 2, recruitment is divided into two phases: Control Phase I and Intervention Phase II. During Control Phase I, standard recruitment methods were employed, including general outreach through participating clinics and pre-existing clinical networks. These efforts did not incorporate specific strategies aimed at enhancing diversity or prioritizing underrepresented populations. In contrast, Intervention Phase II introduced four targeted strategies designed to improve the inclusion of African-American, Hispanic/Latinx individuals, and women.
1. Digital Outreach via BuildClinical: The study leverages a digital recruitment campaign managed by BuildClinical, utilizing targeted online advertisements across various platforms. Prospective participants who engage with the advertisements are directed to a study landing page, where they receive detailed study information and complete a preliminary eligibility screening before being contacted by the study team.
2. Patient Registry-Based Recruitment: Eligible participants will be identified through structured data queries from the STAnford Research Repository (STARR) or EPIC registry. This approach ensures targeted outreach to individuals who meet the study's inclusion criteria while reducing screening burden.
3. Honest Broker Outreach via Stanford RPEP: To maintain privacy compliance, the Stanford Research Participant Engagement Program (RPEP) will conduct Honest Broker outreach via multiple channels, including secure Epic MyHealth messages, postal mail, and provider co-invitations. This method allows potential participants to opt in or out before direct contact with the research team, ensuring ethical and efficient recruitment.
4. Spanish-Speaking Ambassador Program: A dedicated Spanish-speaking ambassador will support recruitment efforts by engaging with Spanish-speaking participants, providing culturally tailored study information, and assisting with the informed consent process. This initiative ensures equitable access for Spanish-speaking individuals and facilitates participation among historically underrepresented populations.
Our TIDE site partners at the Morehouse School of Medicine utilize their own recruitment methods for cohort 3, which uses the following:
Medical residents will be randomized into three screening groups using a block randomization approach to ensure demographic balance across the groups (e.g., age, years in training, prior experience). Each group will utilize a different screening method for patient recruitment:
Arm 1: Resident-Led Manual Screening
Residents apply eligibility criteria manually by reviewing patient EMRs and making judgment-based decisions.
Arm 2: AI-Assisted Screening
AI software, Deep 6, will scan EMRs for inclusion criteria and flag potentially eligible patients. Residents will then validate flagged cases to confirm or deny eligibility.
Arm 3: Coordinator-Led Screening (Control)
Coordinators screen patients independently of AI, applying eligibility criteria consistently across all patient records.
These comprehensive recruitment strategies are designed to enhance enrollment diversity, improve participant engagement, and ensure a balanced distribution of participants across study arms.
Primary and Secondary Endpoints for Cohort 1
Primary Endpoint
* Percentage of participants who consent to participate following text message compared to the percentage of participants who consent to participate following emailoutreach.
Secondary Endpoints
● Percentage of participants who consent following either text message or telephone outreach.
● Percentage of participants who consent after opting out after receiving a call or text message.
* Median time from call/text initiation to participant response among all participants who are contacted and respond.
* Percentage of African American, Hispanic, or Asian participants who consent to participate following text message compared to the percentage of African American, Hispanic, and Asian participants who consent to participate following email outreach.
* Percentage of African American or Hispanic participants who consent to participate following text message compared to the percentage of African American or Hispanic, participants who consent to participate following email outreach.
* Percentage of Asian participants who consent to participate following text message compared to the percentage of Asian participants who consent to participate following email outreach.
Primary and Secondary Endpoints for Cohort 2
Primary Endpoint
● Percentage of participants enrolled who are either African-American or Hispanic/LatinX during Intervention Phase II compared to Control Phase I.
Secondary Endpoints
● Percentage of African-American or Hispanic/LatinX participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of Hispanic/LatinX participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of African-American participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of women participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of African-American, Hispanic/LatinX, or women participants enrolled during Intervention Phase II compared to Control Phase I.
● Percentage of African-American, Hispanic/LatinX, or women participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of Hispanic/LatinX participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of African-American participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of women participants who screen positive during Intervention Phase II compared to Control Phase I.
● Percentage of African-American or Hispanic/LatinX participants contacted through Honest Broker and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants in Control Phase I.
● Percentage of women participants contacted through Honest Broker and enrolled during Intervention Phase II compared to the percentage of women participants in Control Phase I.
● Percentage of African-American or Hispanic/LatinX participants contacted through Patient Registry and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants in Control Phase I.
● Percentage of women participants contacted through Patient Registry and enrolled during Intervention Phase II compared to the percentage of women in Control Phase I.
* Percentage of African-American or Hispanic/LatinX participants contacted through BuildClinical and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants contacted in Control Phase I.
* Percentage of women participants contacted through BuildClinical and enrolled during Intervention Phase II compared to Percentage of women participants enrolled in Control Phase I.
* Percentage of Hispanic/LatinX participants contacted through Lay Coordinator and enrolled during Intervention Phase II compared to the Percentage of African-American or Hispanic/LatinX participants contacted in Control Phase I.
Primary and Secondary Endpoints for Cohort 3
Primary Endpoint ● Screening Accuracy: Accuracy metrics include true positive, true negative, false positive, and false negative rates across the three arms, providing insight into each method's reliability and potential for error.
Secondary Endpoints ● Representativeness: This measures the number and characteristics (e.g., age, race/ethnicity) of patients recruited in each arm, allowing for assessment of demographic representativeness.
● Enrollment Screening Efficiency: This is measured as the average time per screened patient across the three arms. Efficiency will be assessed based on total time to screen each patient from record access to eligibility determination.
* Workload and Satisfaction: Surveys will capture resident and coordinator perceptions of workload, satisfaction, and feasibility of each method, with Likert scales and qualitative feedback (Ellis \& Kasperbauer, 2020).
Statistical Analysis Plan (SAP) Cohort 1 Analysis Methods
The proportion of participants who consent following text message or email-telephoneoutreach will be calculated. Median and interquartile range will be estimated for the time from email /text initiation to participant response.
Cohort 2 Analysis Methods This study aims to increase recruitment through a two-phase trial that will compare a combination of recruitment strategies through 3 distinct cohort-based recruitment strategies to assess their effectiveness to improve participant diversity and engagement. Participants are control phase I or intervention phase II.
The primary statistical test will be a two-sample Z-test for proportions, comparing enrollment percentages in African American/Black and Hispanic/Latino between the control phase I and intervention phase II. The same method will be applied to the secondary endpoints, comparing recruitment rates across demographic subgroups and different recruitment strategies. All tests will be one-sided with α=0.05.
Based on the preliminary data from February 2025, the control phase enrolled 135 participants, with the following distributions:
* African American/Black: 8 (5.92%)
* Hispanic/Latino: 17 (12.6%)
The intervention phase II aims for a 50% increase in African American/Black and Hispanic/Latino enrollment. With a total of 270 participants (135 per phase), the power calculation indicates that the statistical power to detect this significant increase is 100%.
Cohort 3 Analysis Methods This cohort will evaluate the efficiency, accuracy, satisfaction, and representativeness across the three screening arms. The primary metric for assessing efficiency will be the mean screening time per patient. A one-way ANOVA will be conducted to compare mean screening times among the arms, followed by post-hoc tests if significant overall differences are detected. For accuracy, the analysis will be based on true and false positive/negative rates across screening methods. Chi-square tests will be used for categorical comparisons, and logistic regression will be applied to control for potential confounding variables, such as resident training level and experience. Representativeness and satisfaction will be evaluated through the analysis of demographic characteristics, including age, race, and gender along with responses to surveys assessing workload and satisfaction. Chi-square tests will be used to analyze categorical demographic data, while the Kurskal-Wallis test will be employed to compare non-parametric Likert-scale responses across all study arms. Additionally, open-ended feedback will be thematically analyzed to enrich the interpretation of quantitative findings.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypertension
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Randomized open label
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mobile Health Technology
Group Type
EXPERIMENTAL
Digital Hypertension Management System
Intervention Type
OTHER
Mobile health technology using physician- directed, semi-automated management of hypertension
Usual Care
Group Type
ACTIVE_COMPARATOR
Usual Care
Intervention Type
OTHER
The participants will receive usual care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digital Hypertension Management System
Mobile health technology using physician- directed, semi-automated management of hypertension
Intervention Type
OTHER
Usual Care
The participants will receive usual care
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 30-90 yrs.
* Smartphone ownership
* Office SBP: ≥ 140 mm Hg
* ≤ 2 current anti-HTN meds
* Able to add or dose-increase at least 2 of the following classes of medications: ACE-I/ARB, diuretic, calcium channel blocker, beta-blocker, mineralocorticoid receptor antagonists (i.e., at least 2 classes are available for addition or dose- increases after excluding intolerant medications and medications currently at maximum dose)
* English or Spanish-speakers
* Smartphone ownership
* Office SBP: ≥ 140 mm Hg
* ≤ 2 current anti-HTN meds
* Able to add or dose-increase at least 2 of the following classes of medications: ACE-I/ARB, diuretic, calcium channel blocker, beta-blocker, mineralocorticoid receptor antagonists (i.e., at least 2 classes are available for addition or dose- increases after excluding intolerant medications and medications currently at maximum dose)
* English or Spanish-speakers
Exclusion Criteria
* Heart failure with reduced ejection fraction (EF \< 40%)
* ESRD (GFR \<15)
* Renal replacement therapy
* Pregnant
* Myocardial infarction or stroke within preceding 6 months
* Hospitalization for hypertensive emergency or malignant hypertension within preceding 6 months
* Prior solid organ transplantation
* At the clinical discretion of the investigators
* Enrolled in another clinical study
* ESRD (GFR \<15)
* Renal replacement therapy
* Pregnant
* Myocardial infarction or stroke within preceding 6 months
* Hospitalization for hypertensive emergency or malignant hypertension within preceding 6 months
* Prior solid organ transplantation
* At the clinical discretion of the investigators
* Enrolled in another clinical study
Minimum Eligible Age
30 Years
Maximum Eligible Age
90 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Paul Wang
Professor of Medicine (Cardiovascular Medicine), Stanford University Medical Center
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul J Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Health Care
Palo Alto, California, United States
Site Status
RECRUITING
Morehouse School of Medicine
Atlanta, Georgia, United States
Site Status
RECRUITING
Lake Country Medical Group
Eatonton, Georgia, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
63700
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management
NCT04714398
COMPLETED
NA
Technology-Enabled Remote Hypertension Management To Advance Health Equity
NCT06331754
NOT_YET_RECRUITING
NA
Effects of Telemonitoring and Telemedicine Service for Hypertensive Care
NCT01335984
COMPLETED
NA
Telemedicine Management of Hypertension
NCT05424744
COMPLETED
NA
Blood Pressure Monitoring in Hypertensive Populations: Device Testing, Feasibility, Acceptability
NCT05601414
COMPLETED
NA
Efficacy of Home Blood Pressure Monitoring (MONITOR Study)
NCT00921791
COMPLETED
NA
Telemonitoring in Arterial Hypertension
NCT07049289
ACTIVE_NOT_RECRUITING
NA
Behavioral Study to Control Blood Pressure
NCT01035554
COMPLETED
PHASE2/PHASE3
Stepped Intervention for Meds Adherence and Blood Pressure Control
NCT00257101
COMPLETED
NA
Machine Learning to Reduce Hypertension Treatment Clinical Inertia
NCT05406336
NOT_YET_RECRUITING
NA
Mobile Health Management of Hypertension
NCT05856955
NOT_YET_RECRUITING
NA
Home Blood Pressure Telemonitoring and Case Management to Control Hypertension
NCT00781365
COMPLETED
NA
Self-Management of Blood Pressure in Resistant Hypertension
NCT06819241
NOT_YET_RECRUITING
NA
An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment
NCT03209154
ACTIVE_NOT_RECRUITING
NA
Hypertension Management Using Remote Patient Monitoring
NCT05562921
COMPLETED
The Smart Hypertension Control Study
NCT03288142
COMPLETED
NA
Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System
NCT01952119
COMPLETED
NA
Technology for Innovative Monitoring of Cardiovascular Prevention: a RCT
NCT03005470
UNKNOWN
PHASE3
A Study in the Use of Home Blood Pressure Monitoring and Telephone Follow-up to Control Blood Pressure
NCT00662753
COMPLETED
PHASE1
Feasibility and Effectiveness of a Ring-type Blood Pressure Measurement Device
NCT06084065
UNKNOWN
NA
Effectiveness of BP Remote Monitoring With Virtual Physician Management in Hypertensive Patients.
NCT05319418
UNKNOWN
NA
Home Blood Pressure in Hypertension Management
NCT00841308
UNKNOWN
PHASE4
A Detailed Look At What Patients Experience When They Take Part In Hypertension Clinical Trials
NCT05910255
NOT_YET_RECRUITING
Vital Signs Blood Pressure Trial
NCT06272318
NOT_YET_RECRUITING